论文部分内容阅读
目的:研究老年非小细胞肺癌(NSCLC)外周血树突状细胞(DC)功能及与NSCLC进展和生存的关系。方法:选取本院住院NSCLC患者30例作为研究组,30例同年龄段健康人群为对照组,采用流式细胞术(FCM)检测两组人群外周血DC表面分子,同时进行随访,随访结束后对研究组再分为肺癌死亡组和肺癌存活组,并进行统计学处理。结果:研究组患者外周血DC表面分子CD80,CD83,CD86,CD1a平均荧光强度分别为49.46±31.93,41.01±12.72,116.69±13.87和16.83±4.72,对照组分别为95.98±50.27,49.60±14.87,118.11±25.00和19.15±2.32,P值分别为0.000,0.035,0.035,0.008;肺癌死亡组CD80,CD83,CD86,CD1a平均荧光强度分别为44.22±28.90,36.32±8.75,93.17±49.79,14.46±3.11;存活组分别为54.05±34.62,45.93±14.01,98.45±52.20,18.90±4.98,P值分别为0.837,0.035,0.282,0.008。结论:老年NSCLC患者DC表面分子表达较对照组显著降低,说明DC功能抑制;CD80、CD86在存活组与死亡组间无显著差异,CD83、CD1a有显著差异(P<0.05和P<0.01),NSCLC患者CD83、CD1a低表达与患者疾病进展和生存期相关。
Objective: To investigate the function of dendritic cells (DCs) in peripheral blood of elderly patients with non-small cell lung cancer (NSCLC) and its relationship with the progression and survival of NSCLC. Methods: Thirty patients with NSCLC in our hospital were selected as research group and 30 healthy subjects in same age group as control group. Flow cytometry (FCM) was used to detect peripheral blood DCs in both groups. At the same time, follow-up was performed. The study group was further divided into lung cancer death group and lung cancer survival group, and statistical analysis. Results: The mean fluorescence intensity of CD80, CD83, CD86 and CD1a in peripheral blood of study group were 49.46 ± 31.93, 41.01 ± 12.72, 116.69 ± 13.87 and 16.83 ± 4.72 respectively, while the control group were 95.98 ± 50.27 and 49.60 ± 14.87 respectively, 118.11 ± 25.00 and 19.15 ± 2.32 respectively, the P values were 0.000,0.035,0.035 and 0.008 respectively. The average fluorescence intensity of CD80, CD83, CD86 and CD1a in the death group were 44.22 ± 28.90, 36.32 ± 8.75, 93.17 ± 49.79 and 14.46 ± 3.11 ; Survival group were 54.05 ± 34.62,45.93 ± 14.01,98.45 ± 52.20,18.90 ± 4.98, P values were 0.837,0.035,0.282,0.008. CONCLUSION: The expression of DCs on the surface of NSCLC patients is significantly lower than that of the control group, indicating that the DC function is inhibited. CD80 and CD86 have no significant difference between survivors and death patients, but there are significant differences between CD83 and CD1a (P <0.05 and P <0.01) The low expression of CD83 and CD1a in patients with NSCLC correlates with disease progression and survival.